文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重症患者依托咪酯使用与死亡率关联的评价:与氯胺酮的比较

Evaluation of Etomidate Use and Association with Mortality Compared with Ketamine among Critically Ill Patients.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论在重症机械通气患者中,启动机械通气当天使用依托咪酯与住院死亡率高于氯胺酮相关(21.6% vs 18.7%;调整OR 1.28),且不受后续糖皮质激素治疗影响。

该研究利用Premier Healthcare数据库2008–2021年数据,评估重症患者启动有创机械通气(IMV)当天使用依托咪酯与氯胺酮的结局差异。在住院前2天内启动IMV并接受依托咪酯或氯胺酮的患者中,建立22,273对倾向评分匹配。主要分析显示,依托咪酯组住院死亡率高于氯胺酮组(21.6% vs 18.7%;绝对风险差2.8%,95%CI 2.1%–3.6%;调整OR 1.28,95%CI 1.21–1.34)。该关联在各亚组和敏感性分析中一致,且插管后数日使用糖皮质激素未减弱该关联。结论认为,启动IMV当天使用依托咪酯常见,与氯胺酮相比与更高的住院死亡率几率相关,且不依赖于后续糖皮质激素治疗。

要点

  • 在住院前2天内启动IMV并匹配的22,273对患者中,依托咪酯组住院死亡率21.6% vs 氯胺酮组18.7%,绝对风险差2.8%(95%CI 2.1%–3.6%),调整OR 1.28(95%CI 1.21–1.34)。
  • 依托咪酯与住院死亡率升高的关联在各亚组和敏感性分析中一致。
  • 插管后数日使用糖皮质激素未减弱依托咪酯与死亡率的关联。
  • 在1,689,945例接受IMV的患者中,738,855例(43.7%)使用了依托咪酯。

适用人群与场景

  • 2008–2021年Premier Healthcare数据库中的ICU患者,接受有创机械通气(IMV);主要匹配分析限定为住院前2天内启动IMV者。

研究设计与关键结果

  • 研究类型:基于Premier Healthcare数据库的回顾性队列研究,比较启动IMV当天使用依托咪酯与倾向评分匹配的氯胺酮患者。
  • 样本量:共1,689,945例接受IMV患者,其中738,855例(43.7%)使用依托咪酯;在住院前2天内启动IMV者中建立22,273对匹配(依托咪酯 vs 氯胺酮)。
  • 主要终点:住院死亡率,依托咪酯组21.6% vs 氯胺酮组18.7%;绝对风险差2.8%(95%CI 2.1%–3.6%);调整OR 1.28(95%CI 1.21–1.34)。
  • 亚组与敏感性分析:关联一致;插管后数日使用糖皮质激素未减弱依托咪酯与死亡率的关联。

证据类型、等级与局限

  • 证据类型:回顾性数据库队列研究(Premier Healthcare Database)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,启动IMV当天使用依托咪酯与住院死亡率高于氯胺酮相关,且该关联独立于后续糖皮质激素治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Uncertainty remains regarding the risks associated with single-dose use of etomidate. Objectives: To assess the use of etomidate in critically ill patients and compare outcomes for patients who received etomidate versus ketamine. Methods: We assessed patients who received invasive mechanical ventilation (IMV) and were admitted to an ICU in the Premier Healthcare Database between 2008 and 2021. The exposure was receipt of etomidate on the day of IMV initiation, and the main outcome was hospital mortality. Using multivariable regression, we compared patients who received IMV within the first 2 days of hospitalization who received etomidate with propensity score-matched patients who received ketamine. We also assessed whether receipt of corticosteroids in the days after intubation modified the association between etomidate and mortality. Measurements and Main Results: Of 1,689,945 patients who received IMV, nearly half (738,855; 43.7%) received etomidate. Among those who received IMV in the first 2 days of hospitalization, we established 22,273 matched pairs administered either etomidate or ketamine. In the primary analysis, receipt of etomidate was associated with greater hospital mortality relative to ketamine (21.6% vs. 18.7%; absolute risk difference, 2.8%; 95% confidence interval, 2.1%, 3.6%; adjusted odds ratio, 1.28, 95% confidence interval, 1.21,1.34). This was consistent across subgroups and sensitivity analyses. We found no attenuation of the association with mortality with receipt of corticosteroids in the days after etomidate use. Conclusions: Use of etomidate on the day of IMV initiation is common and associated with a higher odds of hospital mortality than use of ketamine. This finding is independent of subsequent treatment with corticosteroids.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wunsch H, Bosch NA, Law AC, et al. Evaluation of Etomidate Use and Association with Mortality Compared with Ketamine among Critically Ill Patients. Am J Respir Crit Care Med. 2024. PMID: 39173173. doi:10.1164/rccm.202404-0813OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。